Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

Clin Cancer Res. 2004 Jun 1;10(11):3927-33. doi: 10.1158/1078-0432.CCR-03-0788.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor*
  • Clinical Trials as Topic
  • Cohort Studies
  • Drug Design
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Prostate-Specific Antigen / biosynthesis*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy*
  • Research Design
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Prostate-Specific Antigen